Stock listing
NASDAQ:COGT Cogent Biosciences, Inc. Stock
Home listing (NASDAQ) of Cogent Biosciences, Inc.
Follow Cogent Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:COGT
$26.72 USD -1.09 (-3.9%)
Close on Nov 20, 2026
- Day range
- $26.62 – $27.83 USDNov 20, 2026
- Volume
- 2.12M sharesNov 20, 2026
- Market cap
- $4.65B USDAt the close on Nov 20, 2026 · price × 174.0M shares outstanding
- 52-week range
- $26.36 – $43.73 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $65.56M USDMedian day 1.92M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:COGT · Home | $26.72 USD | -1.095 (-3.9%) | 2,119,147 | $27.26 | $27.83 | $26.62 | $27.81 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:COGT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $26.72 | -1.095 | -3.9% | $27.26 | $27.83 | $26.62 | 2,119,147 | |
| $27.81 | -0.04 | -0.1% | $27.81 | $28.77 | $27.73 | 2,711,457 | |
| $27.85 | +0.41 | +1.5% | $27.22 | $28.08 | $26.36 | 3,363,427 | |
| $27.44 | -1.12 | -3.9% | $28.71 | $28.81 | $27.23 | 1,449,161 | |
| $28.56 | -0.58 | -2.0% | $29.01 | $29.02 | $28.45 | 1,150,715 | |
| $29.14 | -0.26 | -0.9% | $29.01 | $29.78 | $28.61 | 1,858,718 | |
| $29.40 | -2.24 | -7.1% | $31.93 | $32.33 | $28.80 | 4,513,711 | |
| $31.64 | -1.90 | -5.7% | $33.21 | $33.65 | $31.60 | 2,850,312 | |
| $33.54 | +1.895 | +6.0% | $32.38 | $34.04 | $31.49 | 1,689,876 | |
| $31.65 | +2.065 | +7.0% | $29.53 | $31.69 | $28.97 | 1,481,731 | |
| $29.58 | -1.91 | -6.1% | $31.34 | $31.41 | $29.16 | 2,724,932 | |
| $31.49 | +0.43 | +1.4% | $32.03 | $32.03 | $29.94 | 2,229,450 | |
| $31.06 | +1.33 | +4.5% | $30.08 | $31.27 | $30.06 | 1,876,714 | |
| $29.73 | -1.29 | -4.2% | $31.31 | $31.48 | $29.69 | 1,998,106 | |
| $31.02 | -0.94 | -2.9% | $31.75 | $32.34 | $30.65 | 2,495,131 | |
| $31.96 | -0.27 | -0.8% | $32.86 | $32.86 | $31.68 | 1,507,387 | |
| $32.23 | +0.22 | +0.7% | $31.77 | $32.68 | $31.68 | 1,740,882 | |
| $32.01 | +1.10 | +3.6% | $31.10 | $32.22 | $30.72 | 1,838,062 | |
| $30.91 | -0.30 | -1.0% | $31.41 | $31.55 | $30.52 | 2,205,980 | |
| $31.21 | -0.10 | -0.3% | $30.94 | $31.27 | $30.33 | 1,771,236 | |
| $31.31 | -0.12 | -0.4% | $31.07 | $31.91 | $30.86 | 1,178,296 | |
| $31.43 | +0.19 | +0.6% | $31.26 | $31.94 | $31.20 | 2,099,781 | |
| $31.24 | +1.23 | +4.1% | $30.24 | $31.50 | $30.03 | 2,311,787 | |
| $30.01 | +0.49 | +1.7% | $29.66 | $30.23 | $29.51 | 2,541,218 | |
| $29.52 | +0.01 | 0.0% | $29.47 | $29.98 | $28.77 | 2,783,048 | |
| $29.51 | +1.36 | +4.8% | $28.33 | $29.78 | $28.33 | 3,039,765 | |
| $28.15 | +0.06 | +0.2% | $27.93 | $29.05 | $27.74 | 2,295,507 | |
| $28.09 | -1.69 | -5.7% | $29.46 | $29.46 | $27.85 | 2,995,450 | |
| $29.78 | -1.22 | -3.9% | $30.81 | $31.07 | $29.63 | 1,855,295 | |
| $31.00 | +0.92 | +3.1% | $29.98 | $31.03 | $29.90 | 2,522,272 | |
| $30.08 | -0.06 | -0.2% | $29.71 | $30.66 | $28.69 | 3,643,985 | |
| $30.14 | -0.24 | -0.8% | $30.05 | $30.43 | $29.88 | 1,262,894 | |
| $30.38 | -0.49 | -1.6% | $31.17 | $31.17 | $29.70 | 2,383,802 | |
| $30.87 | -0.15 | -0.5% | $31.26 | $31.37 | $29.93 | 1,792,883 | |
| $31.02 | -0.57 | -1.8% | $32.12 | $32.29 | $30.86 | 1,172,134 | |
| $31.59 | -0.43 | -1.3% | $32.02 | $32.57 | $31.52 | 1,698,630 | |
| $32.02 | +0.36 | +1.1% | $31.74 | $32.76 | $31.49 | 1,960,172 | |
| $31.66 | -0.20 | -0.6% | $31.76 | $32.12 | $31.32 | 1,704,731 | |
| $31.86 | -0.45 | -1.4% | $32.00 | $32.20 | $31.23 | 2,212,923 | |
| $32.31 | +0.88 | +2.8% | $31.55 | $32.71 | $31.05 | 2,979,048 | |
| $31.43 | +0.02 | +0.1% | $31.21 | $31.95 | $30.35 | 2,591,471 | |
| $31.41 | -1.22 | -3.7% | $32.62 | $32.85 | $30.88 | 2,330,314 | |
| $32.63 | +0.63 | +2.0% | $32.23 | $32.85 | $32.06 | 2,036,175 | |
| $32.00 | +0.50 | +1.6% | $31.97 | $32.52 | $31.41 | 3,415,438 | |
| $31.50 | -1.69 | -5.1% | $33.21 | $33.42 | $31.39 | 4,604,077 | |
| $33.19 | +0.65 | +2.0% | $33.07 | $33.64 | $32.88 | 1,189,539 | |
| $32.54 | -0.20 | -0.6% | $32.89 | $33.27 | $32.20 | 1,921,689 | |
| $32.74 | -0.67 | -2.0% | $33.37 | $33.93 | $32.69 | 1,712,424 | |
| $33.41 | 0.00 | 0.0% | $33.42 | $33.58 | $32.85 | 1,437,396 | |
| $33.41 | -0.67 | -2.0% | $34.51 | $35.00 | $33.21 | 1,715,802 | |
| $34.08 | -0.10 | -0.3% | $33.50 | $34.19 | $33.07 | 2,264,643 | |
| $34.18 | -1.10 | -3.1% | $35.09 | $35.57 | $34.08 | 1,587,526 | |
| $35.28 | +0.52 | +1.5% | $34.16 | $35.75 | $33.90 | 2,244,424 | |
| $34.76 | -0.19 | -0.5% | $34.56 | $35.20 | $34.42 | 784,080 | |
| $34.95 | +0.38 | +1.1% | $34.90 | $35.14 | $34.06 | 1,268,646 | |
| $34.57 | -0.11 | -0.3% | $35.18 | $35.82 | $34.01 | 1,181,784 | |
| $34.68 | -0.32 | -0.9% | $34.48 | $34.99 | $34.30 | 1,480,641 | |
| $35.00 | +0.33 | +1.0% | $34.61 | $35.21 | $34.11 | 1,849,678 | |
| $34.67 | -2.42 | -6.5% | $36.66 | $36.85 | $34.53 | 1,771,221 | |
| $37.09 | +0.37 | +1.0% | $36.51 | $37.67 | $36.41 | 1,636,565 | |
| $36.72 | -0.08 | -0.2% | $36.49 | $37.12 | $36.28 | 1,062,781 | |
| $36.80 | +0.57 | +1.6% | $36.56 | $37.08 | $36.44 | 1,394,407 | |
| $36.23 | -0.50 | -1.4% | $36.75 | $37.12 | $36.07 | 1,214,545 | |
| $36.73 | +1.42 | +4.0% | $35.75 | $37.22 | $35.40 | 2,515,752 | |
| $35.31 | -1.54 | -4.2% | $36.31 | $36.70 | $34.91 | 1,943,841 |
Splits
1 split · NASDAQ:COGT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-4 | Consolidation |
- Ticker
- NASDAQ:COGT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 56 slides
Latest news
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $31.65 (+7.0%) on Nov 6, 2026
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
Oct 27, 2026
Closed $32.23 (+0.7%) on Oct 28, 2026
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Sep 15, 2026
Closed $32.74 (-2.0%) on Sep 15, 2026
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Aug 10, 2026
Closed $41.53 (-2.0%) on Aug 10, 2026
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
Jun 30, 2026
Closed $38.70 (-0.1%) on Jun 30, 2026
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
Jun 12, 2026
Closed $33.10 (+1.5%) on Jun 12, 2026
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Jun 12, 2026
Closed $33.10 (+1.5%) on Jun 12, 2026
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
May 30, 2026
Closed $34.81 (-0.4%) on Jun 1, 2026
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
May 28, 2026
Closed $35.38 (+2.5%) on May 28, 2026
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Closed $34.51 (+1.7%) on May 27, 2026
Cogent Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 150 in all · newest Nov 5, 2026 · oldest 2019
- Decks
- 17 decks · latest September 2026
Where Cogent Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:COGT · Home listing · This page | NASDAQ | United States | USD |
| BX Swiss:COGT | BX Swiss | Switzerland | CHF |
| BOATS:COGT | BOATS | United States | USD |
Valuation
Price/book 9.0× against a median of 6.4×: 7th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.08B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 9.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.4×
- Beta vs S&P 500
- 1.30
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cogent Biosciences, Inc. · NASDAQ:COGT | US$4.65B | US$4.08B | n/a | n/a | n/a | 9.0× | n/a | 0.4× | 1.30 |
| SK Biopharmaceuticals Co., Ltd. · KRX:326030 | US$5.08B | US$4.80B | 16.9× | 7.5× | 20.1× | 6.7× | 46.6% | 0.0× | n/a |
| Veradermics, Incorporated · NYSE:MANE | US$5.04B | US$4.25B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.13 |
| Liquidia Corporation · NASDAQ:LQDA | US$4.90B | US$4.68B | n/a | 7.5× | n/a | n/a | −15.2% | n/a | 0.84 |
| Erasca, Inc. · NASDAQ:ERAS | US$4.78B | US$4.18B | n/a | n/a | n/a | 5.2× | n/a | 0.1× | 1.51 |
| Dianthus Therapeutics, Inc. · NASDAQ:DNTH | US$4.76B | US$3.92B | n/a | 1,444× | n/a | 3.8× | n/a | 0.0× | 0.90 |
| PTC Therapeutics, Inc. · NASDAQ:PTCT | US$4.71B | US$3.12B | n/a | 2.7× | n/a | n/a | −9.2% | n/a | 0.88 |
| Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSA | US$4.53B | US$3.97B | 41.4× | 4.2× | 29.9× | 6.4× | 11.6% | 0.0× | 0.57 |
| Travere Therapeutics, Inc. · NASDAQ:TVTX | US$4.51B | US$4.21B | n/a | 6.5× | n/a | 200× | −18.7% | 0.0× | 1.31 |
| Ionis Pharmaceuticals, Inc. · NASDAQ:IONS | US$4.43B | US$4.70B | n/a | 4.9× | n/a | 11.3× | −56.9% | 5.5× | 0.40 |
| Edgewise Therapeutics, Inc. · NASDAQ:EWTX | US$4.37B | US$2.63B | 4.3× | n/a | n/a | 2.7× | n/a | 0.0× | 1.12 |
| Median of the others | US$4.74B | US$4.19B | 16.9× | 6.5× | 25.0× | 6.4× | −12.2% | 0.0× | 0.90 |
Forecasts
9 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 55.82 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.33 · 9 analysts
- Revenue, year to Dec 2026
- 5.45M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Andrew Robbins | Chief Executive Officer & President |
| John Green | Chief Financial Officer |
| Evan Kearns | Chief Legal Officer and Corporate Secretary |
| Christi Waarich | Senior Director, Investor Relations |
| Brad Barnett | Chief Technology Officer |
| Cole Pinnow | Chief Commercial Officer |
| Erin Schellhammer | Chief People Officer |
| Jessica Sachs | Chief Medical Officer |
| John Robinson | Chief Scientific Officer |
| Karen Ferrante | Medical Oncologist and former Pharma-Biotech Executive |
| Matthew E. Ros | Pharma-Biotech Executive |
| Todd E. Shegog | Pharma-Biotech Executive |
Board
| Director | Role |
|---|---|
| Andrew Robbins | Chief Executive Officer & President |
| Arlene M. Morris | Director |
| Chris Cain | Member of the Compensation Committee, Chair of the Science & Technology Committee |
| Karen Ferrante | Medical Oncologist and former Pharma-Biotech Executive |
| Matthew E. Ros | Pharma-Biotech Executive |
| Peter Harwin | Founding Partner, Fairmount Funds Management LLC |
| Todd E. Shegog | Pharma-Biotech Executive |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +7.0% |
| Q2 2026 | Aug 10, 2026 · After close | −6.8% |
| Q1 2026 | May 12, 2026 | +0.6% |
| Q4 2025 | Feb 17, 2026 · Before open | +3.0% |
| Q3 2025 | Nov 7, 2025 · After close | +119.0% |
| Q2 2025 | Aug 5, 2025 · Before open | −5.7% |
| Q1 2025 | May 5, 2025 · Before open | −5.1% |
| Q4 2024 | Feb 25, 2025 · Before open | −6.3% |
| Q3 2024 | Nov 12, 2024 · Before open | −0.2% |
| Q2 2024 | Aug 6, 2024 · Before open | +1.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | +2.5% |
| Q4 2023 | Feb 26, 2024 · Before open | +0.8% |
| Q3 2023 | Nov 2, 2023 · Before open | +4.5% |
| Q2 2023 | Aug 8, 2023 · Before open | +7.6% |
| Q1 2023 | May 9, 2023 · Before open | +2.5% |
| Q4 2022 | Mar 14, 2023 · Before open | +7.5% |
| Q3 2022 | Nov 14, 2022 · Before open | −2.3% |
| Q2 2022 | Aug 9, 2022 · Before open | +3.1% |
| Q1 2022 | May 10, 2022 · Before open | −8.3% |
| Q4 2021 | Mar 15, 2022 · Before open | +4.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 56 slides | September 2026 |
| Technical Presentation (2026) | Technical | 16 slides | 2026 |
| Investor Presentation (December 2025) | Investor deck | 33 slides | Dec 8, 2025 |
| ASH 2025 | Conference | 16 slides | December 2025 |
| Technical Presentation (November 2025) | Technical | 21 slides | Nov 10, 2025 |
| Technical Presentation (July 2025) | Technical | 18 slides | Jul 7, 2025 |
| Jefferies Global Healthcare Conference 2025 | Conference | 15 slides | Jun 5, 2025 |
| ASH 2023 Annual Meeting (Oral Presentation) | Conference | 17 slides | December 2023 |
| CTOS Annual Meeting 2023 | Conference | 11 slides | Nov 1, 2023 |
| American Society of Hematology Annual Meeting 2022 | Conference | 22 slides | Dec 12, 2022 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| European Hematology Association Congress 2022 | Conference | 24 slides | Jun 10, 2022 |
| Investor Presentation (November 2020) | Investor deck | 31 slides | Nov 30, 2020 |
| Unum Therapeutics — Investor Presentation (October 2020) | Investor deck | 22 slides | Oct 5, 2020 |
| Unum Therapeutics — Merger or Acquisition (July 2020) | Merger or acquisition | 22 slides | Jul 6, 2020 |
| Unum Therapeutics — Investor Presentation (January 2020) | Investor deck | 28 slides | Jan 13, 2020 |
| Unum Therapeutics — Cowen and Company 39th Annual Healthcare Conference 2019 | Conference | 28 slides | Mar 7, 2019 |
| Unum Therapeutics — Investor Presentation (January 2019) | Investor deck | 39 slides | Jan 7, 2019 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of shares Closed: US$73.6M raised Use of proceeds: Fund operating expenses and capital expenditures into late 2028, including through potential FDA approvals of bezuclastinib and early commercial launch | Aug 10, 2026 |
| 1.625% convertible senior notes due 2031 Update: US$200M · Jefferies +1 Dealers: Jefferies (co-lead), J.P. Morgan (co-lead) Use of proceeds: Repay $50 million of term loans; bezuclastinib development, regulatory work and commercial launch; other candidates; working capital and general purposes | Nov 11, 2025 |
| Public offering of shares of common stock Made bigger: US$200M · US$31 a share · J.P. Morgan +5 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Leerink Partners (co-lead), Guggenheim Securities (co-lead), LifeSci Capital, Raymond James Use of proceeds: Repay $50 million of term loans; bezuclastinib development, regulatory work and commercial launch; other candidates; working capital and general purposes | Nov 11, 2025 |
| At-the-market programme of shares of common stock Closed: US$39M raised | Nov 3, 2025 |
| Public offering of shares of common stock Closed: US$230M raised · US$9 a share · J.P. Morgan +3 Dealers: J.P. Morgan (co-lead), Leerink Partners (co-lead), Guggenheim Securities (co-lead), LifeSci Capital Use of proceeds: Development, regulatory and commercial preparation for bezuclastinib and other candidates, its commercial launch, working capital and general corporate purposes | Jul 10, 2025 |
| At-the-market programme of common stock Closed: US$25M raised | Feb 25, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Unum Therapeutics, Inc. Priced at US$12.00 a share on Mar 28, 2018.
- Price
- US$12.00 a share
- Shares offered
- 5,770,000 shares of common stock
- Offering size
- US$69.2 million
- Underwriters' option
- Up to 865,500 more shares
- Underwriters
- MORGAN STANLEY, COWEN, SUNTRUST ROBINSON HUMPHREY, WEDBUSH PACGROW · In the order on the cover
- Shares delivered
- On or about Apr 3, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 3, 2017 |
| Filed publicly | Mar 2, 2018 |
| Amended once | Mar 19, 2018 |
| Shares registered with an exchange | Mar 26, 2018 |
| Declared effective by the SEC | Mar 28, 2018 |
| Final prospectus, with the price | Mar 29, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 29, 2018 |
| EFFECT · Notice that a registration is effective | Mar 28, 2018 |
| CERT · Exchange's certificate of listing | Mar 28, 2018 |
| FWP · Free writing prospectus | Mar 27, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 26, 2018 |
| CORRESP · Letter to the SEC | Mar 26, 2018 |
| CORRESP · Letter to the SEC | Mar 26, 2018 |
| S-1/A · Registration statement, amended | Mar 19, 2018 |
| CORRESP · Letter to the SEC | Mar 8, 2018 |
| S-1 · Registration statement | Mar 2, 2018 |
All 14 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Feb 13, 2018 |
| DRS/A · Draft registration statement, amended | Feb 13, 2018 |
| UPLOAD · Letter from the SEC | Dec 4, 2017 |
| DRS · Draft registration statement | Nov 3, 2017 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 29, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 7.87M | 22.5M | 9.73M | 8.36M | 6.36M |
| Cost of revenue | 4.62M | 4.40M | 3.59M | 5.88M | 147.0K | 25.7M | 43.7K | |||
| Gross profit | -4.62M | -4.40M | -3.59M | -5.88M | -147.0K | -17.9M | 22.5M | 9.73M | 8.36M | 6.36M |
| Research and development | 269.8M | 232.7M | 173.8M | 121.6M | 55.9M | 25.7M | 43.7M | 38.3M | 29.8M | 22.0M |
| Selling, general and administrative | 63.6M | 43.3M | 34.4M | 26.2M | 19.6M | 17.4M | 11.0M | 7.45M | 4.68M | 3.43M |
| Operating income | -333.4M | -275.9M | -208.1M | -147.8M | -75.6M | -82.2M | -32.2M | -36.0M | -26.2M | -19.1M |
| Depreciation and amortization | 2.60M | 2.50M | 2.30M | 800.0K | 147.0K | 720.0K | 1.29M | 1.32M | 1.17M | 830.0K |
| EBITDA | -330.8M | -273.4M | -205.8M | -147.0M | -75.4M | -81.5M | -30.9M | -34.7M | -25.0M | -18.2M |
| Interest expense | 3.06M | 0 | 0 | 3.99M | 3.13M | 144.0K | 0 | 0 | 0 | 0 |
| Income before tax | -328.9M | -255.9M | -192.4M | -140.2M | -72.3M | -74.8M | -31.8M | -34.5M | -25.5M | -18.1M |
| Income tax | 0 | -7.60M | -467.0K | -8.36M | -1.56M | 1.47M | -386.0K | -265.0K | ||
| Net income | -328.9M | -255.9M | -192.4M | -140.2M | -72.3M | -74.8M | -31.8M | -34.5M | -25.5M | -18.1M |
| Earnings per share, basic | -2.16 | -1.94 | -1.94 | -1.73 | -1.87 | -16.17 | -4.18 | -1.39 | -2.51 | -2.45 |
| Earnings per share, diluted | -2.16 | -1.94 | -1.94 | -1.73 | -1.87 | -16.17 | -4.18 | -1.39 | -2.51 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 312.0M | 98.2M | 53.2M | 139.9M | 219.7M | 242.2M | 37.4M | 55.7M | 28.3M | 41.3M |
| Short-term investments | 588.8M | 188.9M | 212.5M | 119.4M | 0 | 0 | 22.9M | 12.7M | 27.2M | |
| Receivables | 0 | 2.00M | 1.67M | 830.0K | 928.0K | |||||
| Inventory | 75.0K | |||||||||
| Current assets | 910.4M | 296.5M | 270.8M | 265.0M | 222.6M | 244.9M | 40.6M | 81.0M | 42.4M | 69.7M |
| Property, plant and equipment | 5.46M | 6.47M | 8.34M | 7.78M | 1.71M | 134.0K | 1.86M | 3.25M | 4.11M | |
| Total assets | 937.6M | 327.9M | 313.4M | 300.8M | 232.1M | 250.9M | 49.4M | 85.9M | 49.1M | 75.5M |
| Accounts payable | 9.50M | 12.0M | 10.7M | 5.84M | 3.48M | 732.0K | 3.18M | 1.52M | 1.35M | 1.45M |
| Current liabilities | 64.0M | 55.7M | 38.2M | 26.8M | 17.1M | 13.1M | 13.2M | 24.9M | 11.2M | 8.74M |
| Long-term debt | 222.9M | 0 | ||||||||
| Total debt | 222.9M | 0 | 18.9M | 19.6M | 3.15M | 5.21M | 6.03M | |||
| Total liabilities | 301.2M | 71.6M | 55.6M | 45.1M | 17.9M | 16.2M | 17.7M | 25.7M | 20.8M | 23.2M |
| Shareholders' equity | 636.4M | 256.3M | 257.8M | 255.7M | 214.2M | 234.7M | 31.8M | 60.2M | -48.8M | 52.4M |
| Shares outstanding | 161.0M | 110.5M | 86.1M | 69.9M | 43.8M | 32.3M | 7.67M | 30.1M | 10.2M | 7.40M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -264.4M | -207.8M | -153.6M | -118.6M | -58.8M | -35.9M | -41.5M | -32.5M | -25.8M | -18.6M |
| Capital spending | -1.55M | -573.0K | -2.80M | -6.86M | -1.72M | -320.0K | -33.0K | -549.0K | -912.0K | -3.31M |
| Free cash flow | -266.0M | -208.4M | -156.4M | -125.5M | -60.5M | -35.9M | -41.5M | -33.0M | -26.7M | -21.9M |
| Cash from investing | -399.5M | 38.3M | -97.8M | -124.7M | -1.72M | 8.42M | 23.2M | -10.5M | 13.6M | -30.4M |
| Cash from financing | 878.2M | 214.5M | 163.5M | 163.6M | 38.0M | 232.2M | 108.0K | 70.3M | -729.0K | -40.0K |
| Share buybacks | 1.61M | 55.0K | 124.5M | |||||||
| Change in cash | 214.3M | 44.9M | -87.9M | -79.8M | -22.5M | 204.8M | -18.2M | 27.3M | -13.0M | -49.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 2, 2026 | Material contract | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 27, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 10, 2026 | Current report | SEC |
| 424B5 · Prospectus | Aug 10, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 31, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Feb 17, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 17, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 17, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 22, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| 8-K · Current report | Nov 18, 2025 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 12, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Nov 12, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 10, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 10, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| S-3ASR · Registration statement | Nov 7, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 11, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 11, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 10, 2025 | Results | SEC |
| 424B5 · Prospectus | Jul 9, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jul 8, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 7, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | May 12, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| 424B5 · Prospectus | May 6, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | May 6, 2025 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 22, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 11, 2025 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 11, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 25, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 25, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 6, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 27, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 29, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 12, 2024 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 11, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 8, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 1, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| S-3 · Registration statement | Mar 29, 2024 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 27, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Mar 22, 2024 | Financing | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2024 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 14, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 5, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 23, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 7, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2023 | Results | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 8, 2023 | Offer document | SEC |
This page holds 200 of 616 filings. Open Filings
Cap table
Built by 6ix from Cogent Biosciences, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 173,994,452
- Fully diluted
- 173,994,452
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 173,994,452 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 173,994,452 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert J Perez Other companies: Rapport Therapeutics, Inc. (Director · Since at least Nov 7, 2024); Immunocore Holdings plc (Director · Jan 2, 2024 – Jan 2, 2024 · Past); Third Harmonic Bio Inc. (Director · Sep 14, 2022 – Mar 6, 2023 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 22, 2023 · Past); Spark Therapeutics Inc (Director · Jan 3, 2018 – Dec 17, 2019 · Past); Larimar Therapeutics, Inc. (Director · Sep 24, 2015 – Jun 26, 2019 · Past); Decoy Therapeutics Inc. (Director · Sep 2, 2015 – Jul 26, 2017 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 22, 2017 · Past); AMAG Pharmaceuticals Inc (Director · Jan 26, 2009 – May 16, 2019 · Past); Cubist Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 3, 2006 – Jan 21, 2015 · Past) | Director · Mar 28, 2018 – Jun 14, 2019 · Past |
| Arlene Morris Other companies: Edgewise Therapeutics, Inc. (Director · Since at least May 6, 2024); Palatin Technologies, Inc. (Director · Since at least Jun 22, 2022); Viridian Therapeutics, Inc. (Chief Executive Officer, Willow Advisors · Since at least Jun 8, 2022); Viveve Medical, Inc. (Director · Jan 3, 2023 – Jan 3, 2023 · Past) | Director · Since at least Jun 7, 2022 |
| Chris Cain Other companies: Damora Therapeutics, Inc. (Board Director · Since at least Nov 10, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Viridian Therapeutics, Inc. (Director · Since at least Mar 10, 2025) | Director · Since at least Jul 6, 2020 |
| Matthew Ros Other companies: Verastem, Inc. (Chief Operating Officer · Jan 14, 2025 – Nov 4, 2026 · Past); Epizyme Inc (See Remarks · May 16, 2016 – Aug 16, 2021 · Past) | Pharma-Biotech Executive · Since at least Jul 26, 2019 |
| Peter Harwin Other companies: Oruka Therapeutics, Inc. (Director · Since at least Nov 5, 2026); Damora Therapeutics, Inc. (Chairman of the Board · Since at least May 12, 2026) | Founding Partner, Fairmount Funds Management LLC · Since at least Nov 4, 2026 |
| Chris Cain Other companies: Jade Biosciences, Inc. (Director of Research, Fairmount · Since at least Nov 4, 2026) | Member of the Compensation Committee, Chair of the Science & Technology Committee · Since at least Nov 4, 2026 |
| John Green Other companies: Merrimack Pharmaceuticals Inc (Principal Accounting Officer · Jun 14, 2017 – Jun 14, 2017 · Past) | Chief Financial Officer · Since at least Jan 31, 2019 |
| Jorn Aldag Other companies: Hookipa Pharma Inc (Chief Executive Officer, Director · Apr 17, 2019 – Apr 15, 2024 · Past) | Director · Mar 28, 2018 – Jul 1, 2020 · Past |
| Karen Ferrante Other companies: MacroGenics, Inc. (Director · Since at least May 13, 2021) | Director · Since at least Oct 1, 2020 |
| Todd Shegog Other companies: Forma Therapeutics Holdings Inc (SVP, Chief Financial Officer · Jun 18, 2020 – Oct 14, 2022 · Past) | Pharma-Biotech Executive · Since at least Feb 22, 2021 |
All 20 people
| Person | Seat |
|---|---|
| Andrew Robbins | Chief Executive Officer & President · Since at least Dec 17, 2025 |
| Brad Barnett | Chief Technology Officer · Since at least Nov 5, 2026 |
| Charles Wilson | Chief Executive Officer, Director · Mar 28, 2018 – Mar 1, 2019 · Past |
| Christi Waarich | Senior Director, Investor Relations · Since at least Sep 15, 2026 |
| Cole Pinnow | Chief Commercial Officer · Since at least Dec 17, 2025 |
| Erin Schellhammer | Chief People Officer · Since at least Nov 5, 2026 |
| Evan Kearns | Chief Legal Officer · Since at least Jan 23, 2024 |
| Geoffrey Hodge | Chief Technical Officer · Mar 1, 2019 – Feb 11, 2020 · Past |
| Jessica Sachs | Chief Medical Officer · Since at least Nov 5, 2026 |
| John Robinson | Chief Scientific Officer · Since at least Mar 31, 2021 |
Log in to ask 6ix AI your own questions about Cogent Biosciences, Inc.